Tag Archives: celg

Was Celgene’s Crohn’s Disease Drug Worth The Price?

Big-cap biotech Celgene made its name as a cancer fighter, but now it’s branching out into diseases of the immune system. And one of the biggest tests of this new strategy comes this weekend. At the United European Gastroenterology Week in Vienna, which runs Saturday to Oct. 22, Celgene (CELG) is set to present phase-two data on GED-0301, a treatment for Crohn’s disease, an inflammatory disease of the GI tract. Celgene licensed the drug in April

Celgene, Gilead Lead Big Biotech Stock Movers

Big-cap biotechs were moving in strong volume on the stock market today as Deutsche Bank added several of them to its short-term buy list, after Citi reported back from visits with medical experts. Celgene (CELG) hit a new high above 95 after Deutsche Bank analyst Robyn Karnauskas touted it as a short-term investment idea, saying the read-out of clinical-trial data from a new drug for Crohn’s disease could move the stock in October. The company

Celgene, Alexion Beat Estimates, But Biotechs Fall

Big-cap biotechs Celgene and Alexion Pharmaceuticals modestly beat Q2 estimates and raised their guidance early Thursday, but their shares tumbled as Wall Street seemed to turn against the sector. Celgene’s (CELG) Q2 earnings rose 18% over the year-earlier quarter to 90 cents a share, beating consensus by a penny. Sales increased 17% to $1.87 billion, about $20 million above estimates. The company added $100 million to its full-year revenue